K-CAB FILM-COATED TABLETS 50MG

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Therapeutic

Prescription Only

TABLET, FILM COATED

**DOSAGE AND MODE OF ADMINISTRATION** _For Adult Population:_ - Treatment of Erosive Gastroesophageal Reflux Disease: 50 mg once daily for 4 weeks. For patients who do not heal or have persistent symptoms after 4 weeks, an additional 4-week treatment may be considered. - Treatment of Non-Erosive Gastroesophageal Reflux Disease: 50 mg once daily for 4 weeks. - Treatment of Gastric Ulcer: 50 mg once daily for 8 weeks. - Eradication of _H. pylori_ concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis: Patients with _H. pylori_ infection should be treated with eradication therapy. Tegoprazan 50 mg, clarithromycin 500 mg, and amoxicillin 1 g are orally administered twice daily for 7 days. When selecting appropriate combination therapy, consideration should be given to official national, regional and local guidance regarding bacterial resistance, duration of treatment and appropriate use of antibacterial agents. K-CAB can be taken orally without regard to food. _For Pediatric Population:_ Clinical safety and efficacy of K-CAB in Pediatric and adolescent patients have not been established.